Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells

European Journal of Pharmacology

Volumn 584, Issue 1, 2008, Pages 66-71

  Shi, Yan qiu ^a   Qu, Xian jun ^a   Liao, Yong xiang ^a   Xie, Chun feng ^a   Cheng, Yan na ^a   Li, Song ^a   Lou, Hong xiang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

K562 A02 cells; Multidrug resistance; P glycoprotein; Plagiochin E; Reversal

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIBENZYL DERIVATIVE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN P; MACROCYCLIC COMPOUND; PLAGIOCHIN E; RHODAMINE 123; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MARCHANTIA; MARCHANTIA POLYMORPHA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRIDGED COMPOUNDS; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; P-GLYCOPROTEIN; RHODAMINE 123; STILBENES; TIME FACTORS;

EID: 41149176382     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.039     Document Type: Article

References (28)

1. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., and Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 64 (2002) 573-582
2. Asakawa Y., Toyota M., Tori M., and Hashimoto T. Chemical structures of macrocyclic bis(bibenzyls) isolated from liverworts (Hepaticae). Spectroscopy 14 (2000) 149-175
3. Borowski E., Bontemps-Gracz M.M., and Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim. Pol. 52 (2005) 609-627
4. Chearwaw W., Anuchapreeda S., Nandigama K., Ambudkar S.V., and Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcurmin I, II, and III purified from Turmeric powder. Biochem. Pharmacol. 68 (2004) 2043-2052
5. Di Pietro A., Conseil G., Perez-Victoria J.M., Dayan G., Baubichon-Cortay H., Trompier D., Steinfels E., Jault J.M., de Wet H., Maitrejean M., Comte G., Boumendjel A., Mariotte A.M., Dumontet C., McIntosh D.B., Goffeau A., Castanys S., Gamarro F., and Barron D. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell. Mol. Life Sci. 59 (2002) 307-322
6. Galski H., Sivan H., Lazarovici P., and Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk. Res. 30 (2006) 1151-1158
7. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev., Cancer 2 (2002) 48-58
8. Green L.J., Marder P., and Slapak C.A. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem. Pharmacol. 61 (2001) 1393-1399
9. Jain S., Laphookhieo S., Shi Z., Fu L.W., Akiyama S., Chen Z.S., Youssef D.T., van Soest R.W., and El Sayed K.A. Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. J. Nat. Prod. 70 (2007) 928-931
10. Ji B.S., and He L. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. J. Pharm. Pharmacol. 59 (2007) 1011-1015
11. Ji B.S., He L., and Liu G.Q. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci. 77 (2005) 2221-2232
12. Kim Y.K., Song Y.J., Seo D.W., Kang D.W., Lee H.Y., Rhee D.K., Han J.W., Ahn C.M., Lee S., and Kim S.N. Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein. Biochem. Biophys. Res. Commun. 355 (2007) 136-142
13. Kitagawa S. Inhibitory effects of polyphenols on P-glycoprotein-mediated transport. Biol. Pharm. Bull. 29 (2006) 1-6
14. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11 (2000) 265-283
15. Labeed F.H., Coley H.M., Thomas H., and Hughes M.P. Assessment of multidrug resistance reversal using dielectrophoresis and flow cytometry. Biophys. J. 85 (2003) 2028-2034
16. Lehnert M., de Giuli R., and Twentyman P.R. Sensitive and rapid bioassay for analysis of P-glycoprotein-inhibiting activity of chemosensitizers in patient serum. Clin. Cancer Res. 2 (1996) 403-410
17. Leng P., Guo X.L., Yang Y., and Lou H.X. Primary study of antifungal activities and reversal of fluconazole resistance of Plagiochin E. Chin. Pharm. J. 3 (2007) 314-317
18. Limtrakul P., Anuchapreeda S., and Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids, Biomed. Chromatogr. Cancer 4 (2004) 13
19. Liu Z.L., Onda K., Tanaka S., Toma T., Hirano T., and Oka K. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother. Pharmacol. 49 (2002) 391-397
20. Marbeuf-Gueye C., Salerno M., Quidu P., and Garnier-Suillerot A. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceina cetoxymethyl ester by PAK-104P. Eur. J. Pharmacol. 391 (2000) 207-216
21. Niu C., Qu J.B., and Lou H.X. Antifungal bis[bibenzyls] from the Chinese liverwort Marchantia polymorpha L. Chem. Biodivers 3 (2006) 34-40
22. Qi J., Liu N., Zhou Y., Tan Y., Cheng Y., Yang C., Zhu Z., and Xiong D. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem. Biophys. Res. Commun. 349 (2006) 303-309
23. Qu X.J., Yang J.L., Russell P.J., and Goldstein D. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J. Urol. 172 (2004) 733-738
24. Teodori E., Dei S., Martelli C., Scapecchi S., and Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of P-glycoprotein and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7 (2006) 893-909
25. Ushigome F., Takanaga H., Matsuo H., Yanai S., Tsukimori K., Nakano H., Uchiumi T., Nakamura T., Kuwano M., Ohtani H., and Sawada Y. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. 408 (2000) 1-10
26. Wang G.H., Chen H.F., Huang M.H., Wang N.L., Zhang J.C., Zhang Y., Bai G.R., Fong W.F., Yang M.S., and Yao X.S. Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Cancer Lett. 241 (2006) 102-109
27. Wu J.Y., Fong W.F., Zhang J.X., Leung C.H., Kwong H.L., Yang M.S., Li D., and Cheung H.Y. Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani. Eur. J. Pharmacol. 473 (2003) 9-17
28. Xu D., Lu Q., and Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett. 243 (2006) 274-280